NCT07458815 Vitamin D for Acute Intracerebral Hemorrhage
| NCT ID | NCT07458815 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Hong Kong |
| Condition | Intracerebral Hemorrhage |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-03-01 |
| Primary Completion | 2027-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2026-03-01 with a primary completion date of 2027-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Intracerebral hemorrhage (ICH) is the most deadly and debilitating form of stroke. To date, effective treatment that could improve the functional outcome of ICH remained elusive. In a mice model of ICH, it was demonstrated that high dose Vitamin D (VitD) treatment enhanced hematoma resolution by promoting reparative macrophage differentiation and improved neurobehavioral performance in mice. Hence, this pilot study aimed to investigate the feasibility and safety of VitD treatment for ICH in human subjects. VICToHR is a prospective, randomized, open-label, blinded-endpoint (PROBE) trial. Participants will be randomized 1:1 to receive either VitD or standard care (control). The intervention group will receive VitD 4000 IU daily for 2 weeks, followed by 1000 IU daily for 24 weeks. The primary outcomes are the rate of hematoma resolution at 14 days and the incidence of hypercalcemia and VitD toxicity. Hematoma volume will be assessed by a neuroradiologist who is blinded to treatment allocation.
Eligibility Criteria
Inclusion Criteria: * Spontaneous ICH diagnosis * Age ≥ 18 years * Within 96 hours of ICH * Premorbid Modified Rankin Scale of ≤2 * Supratentorial ICH * ICH volume ≥2 mL Exclusion Criteria: * Expected life expectancy of \<1 year * Glasgow Coma Scale \<9 * Anticipated surgical evacuation of hematoma * Inability to participate in follow-up activity * Hypercalcemia * Hyperphosphatemia * History of kidney stones * Bleeding tendency * Severe renal impairment * Severe liver impairment * Known contraindication or allergy to vitamin D
Contact & Investigator
Kay Cheong Teo, MBBS, MD
PRINCIPAL INVESTIGATOR
The University of Hong Kong
Frequently Asked Questions
Who can join the NCT07458815 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Intracerebral Hemorrhage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07458815 currently recruiting?
Yes, NCT07458815 is actively recruiting participants. Contact the research team at kcteo@hku.hk for enrollment information.
Where is the NCT07458815 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong.
Who is sponsoring the NCT07458815 clinical trial?
NCT07458815 is sponsored by The University of Hong Kong. The principal investigator is Kay Cheong Teo, MBBS, MD at The University of Hong Kong. The trial plans to enroll 40 participants.